121 related articles for article (PubMed ID: 8666362)
1. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
Pacinda SJ; Ledet SC; Gondo MM; Langston C; Brown RW; Carmona PA; Franklin RB; Roggli VL; Cagle PT
Hum Pathol; 1996 Jun; 27(6):542-6. PubMed ID: 8666362
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
3. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
4. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
5. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies.
Bodner SM; Koss MN
Hum Pathol; 1996 Nov; 27(11):1117-23. PubMed ID: 8912818
[TBL] [Abstract][Full Text] [Related]
7. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
Zhang J; Liu H; Li S; Gu C
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(3A):1689-95. PubMed ID: 9673391
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
Ito E; Saito K; Takizawa T; Koike M
J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
[TBL] [Abstract][Full Text] [Related]
10. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms.
Nakatani Y; Kitamura H; Inayama Y; Kamijo S; Nagashima Y; Shimoyama K; Nakamura N; Sano J; Ogawa N; Shibagaki T; Resl M; Mark EJ
Am J Surg Pathol; 1998 Apr; 22(4):399-411. PubMed ID: 9537466
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
13. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
16. Detection of MDM2-proto-oncogene in paraffin embedded human bronchial epithelium.
Wiethege T; Voss B; Müller KM
J Cancer Res Clin Oncol; 1994; 120(4):252-5. PubMed ID: 8288680
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T
Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis.
Girod SC; Cesarz D; Fischer U; Krueger GR
Anticancer Res; 1995; 15(4):1453-7. PubMed ID: 7654034
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(2A):1167-73. PubMed ID: 9615783
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
